Sodium nitroprusside-enhanced cardiopulmonary resuscitation has shown superior resuscitation rates and neurologic outcomes in large animal models supporting the need for a randomized human clinical trial. This study is the first to show nonselective pulmonary vasodilation as a potential mechanism for the hemodynamic benefits. The pulmonary shunting that is created requires increased oxygen treatment, but the overall improvement in blood flow increases minute oxygen delivery to tissues. In this context, hypoxemia is an important safety endpoint and a 100% oxygen ventilation strategy may be necessary for the first human clinical trial.
Keywords: A-a, alveolar-arterial; ACLS, advanced cardiac life support; BLS, basic life support; CBF, carotid blood flow; CPP, coronary perfusion pressure; CPR, cardiopulmonary resuscitation; FiO2, fraction of inspired oxygen; ITD, impedance threshold device; ROSC, return of spontaneous circulation; SNP, sodium nitroprusside; SNPeCPR, sodium nitroprusside–enhanced cardiopulmonary resuscitation; VF, ventricular fibrillation; cardiopulmonary resuscitation; coronary perfusion pressure; lactic acid; pulmonary vasodilation; sodium nitroprusside.
© 2020 The Authors.